All In Biotech

Drug Trial Radar · NCT07340567

Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test

Tailoring the Decision for Adjuvant Chemotherapy Using Circulating Tumour DNA, in Patients With Stage III Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 2,450 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,450

Planned (sponsor's estimate)

Start

Jul 20, 2026

Primary completion

Nov 1, 2032

Study completion Nov 1, 2035

Sponsor

Lead sponsor
UNICANCERAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Natera, Inc.
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CIRCULATE-III is an international, multicenter, open-label, randomized phase III trial designed to use ctDNA as a selection criterion for intensification or de-escalation of adjuvant chemotherapy. Eligible patients are randomly assigned to the following treatment groups: * Patients who test negative for ctDNA receive either capecitabine for 6 months (experimental group) or oxaliplatin + capecitabine for 3 months (standard group). * Patients who test positive for ctDNA receive either FOLFIRINOX for 6 months (experimental group) or FOLFOX for 6 months (standard group). Patient participation in the trial will not exceed 66 months after randomization, including a maximum treatment duration of 6 months and a follow-up period of 60 months.

Conditions

  • Colorectal Cancer

Interventions

  • CapecitabineDrug

    De-escalation treatment (capecitabine \[CAPE\] for 6 months). Or Standard treatment (CAPOX for 3 months)

  • OxaliplatinDrug

    Standard treatment (CAPOX for 3 months)

  • FolfirinoxDrug

    Escalation treatment (5FU + irinotecan + oxaliplatin \[FOLFIRINOX\] for 6 months)

  • FOLFOX regimenDrug

    Standard treatment (FOLFOX for 6 months)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Non-inferiority of 6-month CAPE vs 3-month CAPOX ACT in terms of 3-year Disease Free Survival ctDNA-negative cohortTime frame: DFS will be defined as time from date of randomization until the date of first documented recurrence local or metastatic, date of second colorectal cancer, or date of death from any cause wichever came first, assessed up to 42 months.
  2. Superiority of 6-month FOLFIRINOX vs 6-month FOLFOX ACT in terms of 3-year Disease Free Survival ctDNA-positive cohortTime frame: DFS will be defined as time from date of randomization until the date of first documented recurrence local or metastatic, date of second colorectal cancer, or date of death from any cause, wichever came first, assessed up to 42 months.

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Institut Gustave Roussy

    Villejuif, France

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

  • Skäne University Hospital

    Lund, Sweden

  • Södersjukhuset

    Stockholm, Sweden

  • Onkologikliniken

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.